A new vaccine to prevent herpes zoster

New England Journal of Medicine

Volumn 372, Issue 22, 2015, Pages 2149-2150

  Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; PHOSPHORYL LIPID A; PLACEBO; QS 21; VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; EDITORIAL; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INJECTION SITE REACTION; NONHUMAN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UNITED STATES; VACCINATION; FEMALE; IMMUNOLOGY; MALE;

FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE;

EID: 84929917322     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1505050     Document Type: Editorial

References (10)

1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
2. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8.
3. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087-96.
4. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10:471-86.
5. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068-77.
6. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
7. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 2014;124:2921-9.
8. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34.
9. Studahl M, Petzold M, Cassel T. Disease burden of herpes zoster in Sweden - predominance in the elderly and in women: a register based study. BMC Infect Dis 2013;13:586.
10. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60:900-9.